Summary of Use during Lactation

No information is available on the use of pacritinib during breastfeeding. The manufacturer recommends that breastfeeding be withheld during therapy and for 2 weeks after the last dose. An alternate drug is preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Pacritinib

CAS Registry Number

937272-79-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Enzyme Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors

Signal Transduction Inhibitors

Protein Kinase Inhibitors